Dallan Murray - Sarepta Therapeutics VP Officer
| S1RP34 Stock | BRL 40.08 0.39 0.96% |
Insider
Dallan Murray is VP Officer of Sarepta Therapeutics
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Dallan Murray Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dallan Murray against Sarepta Therapeutics stock is an integral part of due diligence when investing in Sarepta Therapeutics. Dallan Murray insider activity provides valuable insight into whether Sarepta Therapeutics is net buyers or sellers over its current business cycle. Note, Sarepta Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sarepta Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dallan Murray over a week ago Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3 | ||
Dallan Murray over a week ago Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3 | ||
Dallan Murray over a week ago Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3 | ||
Dallan Murray over two weeks ago Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3 |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1149) % which means that it has lost $0.1149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.591) %, meaning that it generated substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Sarepta Therapeutics has accumulated 1.1 B in total debt with debt to equity ratio (D/E) of 2.19, implying the company greatly relies on financing operations through barrowing. Sarepta Therapeutics has a current ratio of 6.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sarepta Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Sarepta Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sarepta Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sarepta to invest in growth at high rates of return. When we think about Sarepta Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael McMullen | Agilent Technologies | 62 | |
| Pedro Ripper | Bemobi Mobile Tech | 50 | |
| Mark Murphy | Micron Technology | 55 | |
| Kareem Chin | Warner Music Group | N/A | |
| Ryan Richardson | BIONTECH SE DRN | 44 | |
| Jan Siegmund | Cognizant Technology Solutions | 59 | |
| Michael Drexler | Warner Music Group | N/A | |
| Jennifer Johnson | Apartment Investment and | 50 | |
| Sean Marett | BIONTECH SE DRN | 58 | |
| Michael Bokan | Micron Technology | 62 | |
| Ozlem MD | BIONTECH SE DRN | 56 | |
| Elizabeth Likovich | Apartment Investment and | N/A | |
| Anand Bahl | Micron Technology | N/A | |
| JD Esq | Warner Music Group | 65 | |
| Lee Hodges | Apartment Investment and | N/A | |
| Sylke Maas | BIONTECH SE DRN | N/A | |
| Rashmi Vasisht | Cognizant Technology Solutions | N/A | |
| Wesley Powell | Apartment Investment and | 43 | |
| Tom Marchant | Apartment Investment and | N/A | |
| Allison Ballmer | Agilent Technologies | N/A | |
| Michael Tang | Agilent Technologies | 49 | |
Management Performance
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Ciambrone, Ex Operations | ||
| Dallan Murray, VP Officer | ||
| Ian Estepan, Ex CFO | ||
| Douglas Esq, CEO Pres | ||
| Alison Nasisi, Chief VP | ||
| Bilal Arif, VP Operations | ||
| Diane Berry, Sr Affairs | ||
| Ryan Brown, Gen VP | ||
| Louise RodinoKlapac, Chief VP | ||
| Mary Jenkins, Sr Relations |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.82) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 56.41 B | |||
| Shares Outstanding | 1.76 B | |||
| Price To Book | 25.76 X | |||
| Price To Sales | 67.46 X | |||
| Revenue | 701.89 M | |||
| Gross Profit | (165.84 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Sarepta Stock
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Sarepta Stock refer to our How to Trade Sarepta Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.